181 related articles for article (PubMed ID: 33361334)
41. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
42. Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron.
Heim C; Spring AK; Kirchgäßner S; Schwarzer D; Hartmann MD
Biochem Biophys Res Commun; 2023 Feb; 646():30-35. PubMed ID: 36701892
[TBL] [Abstract][Full Text] [Related]
43. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.
Verano AL; You I; Donovan KA; Mageed N; Yue H; Nowak RP; Fischer ES; Wang ES; Gray NS
ACS Chem Biol; 2022 Sep; 17(9):2404-2410. PubMed ID: 36007246
[TBL] [Abstract][Full Text] [Related]
44. PDLIM7 Synergizes With PDLIM2 and p62/Sqstm1 to Inhibit Inflammatory Signaling by Promoting Degradation of the p65 Subunit of NF-κB.
Jodo A; Shibazaki A; Onuma A; Kaisho T; Tanaka T
Front Immunol; 2020; 11():1559. PubMed ID: 32849529
[TBL] [Abstract][Full Text] [Related]
45. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
46. Design and Development of IKZF2 and CK1α Dual Degraders.
Miyamoto DK; Curnutt NM; Park SM; Stavropoulos A; Kharas MG; Woo CM
J Med Chem; 2023 Dec; 66(24):16953-16979. PubMed ID: 38085607
[TBL] [Abstract][Full Text] [Related]
47. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
48. Casein kinase 1 α phosphorylates the Wnt regulator Jade-1 and modulates its activity.
Borgal L; Rinschen MM; Dafinger C; Hoff S; Reinert MJ; Lamkemeyer T; Lienkamp SS; Benzing T; Schermer B
J Biol Chem; 2014 Sep; 289(38):26344-26356. PubMed ID: 25100726
[TBL] [Abstract][Full Text] [Related]
49. Basic region of residues 228-231 of protein kinase CK1alpha is involved in its interaction with axin: binding to axin does not affect the kinase activity.
Sobrado P; Jedlicki A; Bustos VH; Allende CC; Allende JE
J Cell Biochem; 2005 Feb; 94(2):217-24. PubMed ID: 15565646
[TBL] [Abstract][Full Text] [Related]
50. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Furihata H; Yamanaka S; Honda T; Miyauchi Y; Asano A; Shibata N; Tanokura M; Sawasaki T; Miyakawa T
Nat Commun; 2020 Sep; 11(1):4578. PubMed ID: 32929090
[TBL] [Abstract][Full Text] [Related]
51. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
Beedie SL; Huang PA; Harris EM; Strope JD; Mahony C; Chau CH; Vargesson N; Figg WD
FASEB J; 2020 Sep; 34(9):11395-11404. PubMed ID: 32677118
[TBL] [Abstract][Full Text] [Related]
52. Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR.
Sudha G; Yamunadevi S; Tyagi N; Das S; Srinivasan N
BMC Struct Biol; 2012 Nov; 12():28. PubMed ID: 23148689
[TBL] [Abstract][Full Text] [Related]
53. HECT domain-containing E3 ubiquitin ligase NEDD4L negatively regulates Wnt signaling by targeting dishevelled for proteasomal degradation.
Ding Y; Zhang Y; Xu C; Tao QH; Chen YG
J Biol Chem; 2013 Mar; 288(12):8289-8298. PubMed ID: 23396981
[TBL] [Abstract][Full Text] [Related]
54. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
55. Cereblon-mediated degradation of the amyloid precursor protein via the ubiquitin-proteasome pathway.
Kurihara T; Asahi T; Sawamura N
Biochem Biophys Res Commun; 2020 Mar; 524(1):236-241. PubMed ID: 31983437
[TBL] [Abstract][Full Text] [Related]
56. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
57. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
58. Cereblon: promise and challenges for combating human diseases.
Kim HK; Seol JE; Ahn SW; Jeon S; Park CS; Han J
Pflugers Arch; 2021 Nov; 473(11):1695-1711. PubMed ID: 34553266
[TBL] [Abstract][Full Text] [Related]
59. Casein kinase 1α regulates murine spermatogenesis via p53-Sox3 signaling.
Lu C; Zhang D; Zhang J; Li L; Qiu J; Gou K; Cui S
Development; 2022 Jul; 149(13):. PubMed ID: 35698877
[TBL] [Abstract][Full Text] [Related]
60. A novel cereblon modulator for targeted protein degradation.
Kim SA; Go A; Jo SH; Park SJ; Jeon YU; Kim JE; Lee HK; Park CH; Lee CO; Park SG; Kim P; Park BC; Cho SY; Kim S; Ha JD; Kim JH; Hwang JY
Eur J Med Chem; 2019 Mar; 166():65-74. PubMed ID: 30684871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]